^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

MQ710

i
Other names: MQ710
Associations
Company:
Imvaq Therap
Drug class:
Immunostimulant
Related drugs:
Associations
4ms
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer (clinicaltrials.gov)
P1, N=5, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting | N=56 --> 5
Enrollment closed • Enrollment change • Combination therapy • Checkpoint inhibition
|
BRAF (B-raf proto-oncogene)
|
Keytruda (pembrolizumab) • MQ710
over1year
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer (clinicaltrials.gov)
P1, N=56, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: May 2025 --> May 2028 | Trial primary completion date: May 2025 --> May 2028
Trial completion date • Trial primary completion date • Combination therapy • Checkpoint inhibition
|
BRAF (B-raf proto-oncogene)
|
PD-L1 expression • BRAF mutation
|
Keytruda (pembrolizumab) • MQ710
over1year
New P1 trial • Combination therapy • Checkpoint inhibition
|
BRAF (B-raf proto-oncogene)
|
PD-L1 expression • BRAF mutation
|
Keytruda (pembrolizumab) • MQ710